Joseph Sullivan

Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome. Zogenix said that its trial met its primary objective of...

Joseph Sullivan, Legg Mason (NYSE: LM) president and CEO, discussed the company's renewed commitment to their model, and their plan to achieve better stability, as a guest on CNBC's Squawk Box Tuesday morning. So where do they stand now? "We do have about two-thirds of our assets in fixed...